alphageneronlogo.jpg
Alphageneron Announces Successful Completion of FDA Pre-IND Meeting of Proposed Phase II Clinical Trial for NK Cell Therapy with Advanced (stage III & Stage IV) NSCLC Patients
18 oct. 2021 10h58 HE | Alphageneron Pharmaceuticals
CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), a clinical stage pharmaceutical company with a robust product portfolio of...
alphageneronlogo.jpg
Alphageneron to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th, 2021
25 juin 2021 19h21 HE | Alphageneron Pharmaceuticals
CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), a privately-held clinical-stage biopharmaceutical company developing...
alphageneronlogo.jpg
Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide
04 févr. 2021 11h35 HE | Alphageneron Pharmaceuticals
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc., (Alphageneron) signed an Exclusive License Agreement with Multimmune GmbH, of Munich, Germany, (Multimmune) on...